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The current tuberculosis vaccine is a live vaccine derived fromMycobacterium
bovis and attenuated by serial in vitro passaging. All vaccine substrains in use
stem from one source, strain Bacille Calmette-Guérin. However, they differ in
regions of genomic deletions, antigen expression levels, immunogenicity, and
protective efficacy
1
. As a RecA phenotype increases genetic stability and may
contribute restricting the ongoing evolution of the various BCG substrains, we
aimed to inactivate recA by allelic replacement in BCG vaccine strains
representing different phylogenetic lineages (Pasteur, Frappier, Denmark,
Russia). Homologous gene replacement was successful in three out of four
strains. However, only illegitimate recombination was observed in BCG
substrain Russia. Sequence analyses of recA revealed that a single nucleotide
insertion in the 5’ part of recA led to a translational frameshift with an early stop
codon making BCG Russia a natural recA mutant. At the protein level BCG
Russia failed to express RecA. According to phylogenetic analyses BCG Russia is
an ancient vaccine strain most closely related to the parental M. bovis
1
. Our data
suggest that recA inactivation in BCG Russia occurred early and is in part
responsible for its high degree of genomic stability, resulting in a substrain that
has less genetic alterations than other vaccine substrains with respect toM. bovis
AF2122/97 wild-type.
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2Tuberculosis is an infectious disease of enormous global importance. It is estimated
that about one third of the human population is latently infected withMycobacterium
tuberculosis with 1.6 million people dying annually from the disease
2
. The currently
employed tuberculosis vaccine, Mycobacterium bovis Bacille Calmette-Guérin (BCG)
was originally derived from a virulent strain ofM. bovis back to 1921, by repeated
passages on potato slices soaked in glycerol-ox byle. The primary attenuation is
attributed to loss of RD1 locus, which affects a protein secretion pathway
3-6
.
Subsequent propagation of BCG in several laboratories around the world resulted in
further in vitro evolution, which is still ongoing. Genetic alterations are mainly due to
deletions and duplications
1
, although single nucleotide polymorphisms (e.g. in sigK)
have also been described
7
. The various genetic alterations – some presumably
involving RecA-mediated recombination - affect the antigenic, protective, and
metabolic properties of BCG. Thus, the term BCG does not refer to an entity but
comprises a set of different substrains. Since the early sixties, freeze dried and
lyophilized secondary seed lots are used as source of commercially available vaccine
strains. WHO vaccine production guidelines
8
call for fresh cultures from secondary
seed lots and propose not to exceed twelve passages from the primary seed lot. These
recommendations have been modified recently, suggesting not to exceed four
passages as phenotypic alterations were observed in vaccine batches undergoing as
little as twelve subcultivations
9
.
To establish BCG as a vector for stable heterologous antigen expression we
intended to stabilize the genome of four BCG substrains representing different
phylogenetic lineages by deletion of recA. A recA phenotype is desirable for live
mycobacterial vaccines as homologous recombination is an important contributor of
genomic evolution
10,11
. We constructed a replacement vector (Suppl. Fig. 1 online)
carrying an unmarked, inactive deletion of the recA allele. In this vector, a
hygromycin resistance cassette and the counterselectable marker sacB flank recA.
Transformation of this kind of vector allows generation of allelic replacement mutants
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3by two subsequent selection steps. In a first step, transformants that have integrated
the knock-out plasmid into the bacterial chromosome are selected on hygromycin B
containing media. Integration of the vector by homologous recombination, i. e. 3’ or
5’ of the genomic recA, is revealed by Southern blot analyses. In a second step,
sucrose-selection is used to select for mutants that have undergone a second
intramolecular recombination resulting either in inactivation of the recA gene or in
reversion to wild-type.
Most of the transformants obtained in substrains Pasteur, Frappier, and
Denmark resulted from homologous integration of the targeting vector (3’or 5’) at the
recA locus (Suppl. Table 1 online). Subsequent counter-selection of clones arising
from homologous recombination events readily resulted in recA deletion mutants as
demonstrated by Southern blot analyses (Suppl. Fig. 2 online). In striking contrast, all
transformants (16/16 analyzed) of substrain Russia resulted from illegitimate
recombination (Suppl. Table 1 and Suppl. Fig. 2 online).
The absence of marker integration by homologous recombination prompted us
to examine the genomic recA sequence in BCG Russia in comparison to the annotated
sequence of BCG Pasteur 1173P2
1
. We found a single insertional mutation 413 bp
from the recA start (Fig. 1), which leads to a translational frameshift and a premature
stop codon at amino acid position 140 in the major central RecA domain (residues 31-
269). The truncated RecA has a length of 139 instead of 790 amino acids and lacks
the complete C-terminal part of the protein including loops L1 (residues 156-165) and
L2 (195-210) implicated in DNA binding
12
. BCG Frappier, Denmark, and Pasteur
recA were identical with the annotated reference sequence encoding a functional
RecA.
Bacteria respond to DNA-damage by coordinated expression of a multitude of
genes involved in repair and control of cell division – the SOS response
13
. The SOS
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4response was induced by addition of the DNA-damaging agent mitomycin C (0.2 g
mL
-1
) to a BCG culture, followed by incubation for an additional 24 hours
14
. Western
blot analysis using a RecA antibody demonstrated induction of RecA in strain BCG
Pasteur, but absence and failure of induction of RecA in BCG Russia (Fig. 2). A
genetically engineered BCG Pasteur recA mutant (this study) was used as a negative
control.
Replication errors, transpositions and recombination events contribute to
genetic alterations and drive genome evolution. For BCG various differences in
morphology, growth rate, protein expression and genetic make-up have been noted
among commercially available substrains
15
. This is presumably a result of the
numerous serial passages on natural (potato slices trenched in ox bile) and artificial
media, which have led to the acquisition of genomic alterations and further
attenuation. Of note, meta-analyses of BCG vaccination trials have indicated
protective efficacies ranging from 0-80 %. A correlation between the number of serial
in vitro passages and the decrease in protective efficacy has been observed
16
. Several
reasons have been put forward to explain the varying protective efficacies of BCG,
among others genetic differences between vaccine substrains as well as within an
individual substrain
1
. More recently it has been suggested that the protective efficacy
of ancient vaccine strains (Fig. 3) may be superior to that of the later ones that are
more widely used
1
.
Comparative genomics indicate that recombination events are a major driving
force of bacterial evolution
11
. There is extensive evidence for large-scale
rearrangements, duplications and deletions resulting from homologous recombination
in M. leprae
17
, M. tuberculosis
18
andM. bovis BCG
19
. Half of the proteins present in
the tubercle bacillus originate from gene duplications. Tandem duplications are
generally caused by unequal crossover between homologous sequences or by
recombination of short DNA homologies. Homologous recombination between
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5similar sequences may invert or delete genes. Several deletions in the M. tuberculosis
H37Rv genome resulted from recombination between adjacent repeats of IS6110
elements
18,20
. Sometimes, the molecular mechanisms underlying alterations at
particular loci remain obscure and subsequent alterations may mask initial events, e.g.
tandem duplication of the DU2 region inM. bovis BCG Pasteur arose from
duplication of a 100 kb genomic segment that subsequently incurred an internal
deletion of 64 kb
19
. Comparative genome and transcriptome analyses indicate that
BCG Russia is an ancient BCG strain most closely related to the original strain
attenuated by Calmette and Guérin
1
. However, a key piece of the puzzle was missing.
What was the molecular mechanism underlying the high degree of genome
conservation in BCG Russia? Here, analysis of the recA locus provides a possible
clue. RecA, which is the key element of homologous recombination and a driving
force in mycobacterial genome evolution, is disrupted by single nucleotide insertion
in BCG Russia. This mutation results in a frameshift and premature translational stop
and most probably contributed to the genome stability of this substrain of BCG.
Methods
Bacterial strains. Escherichia coli DH5 was obtained from Pharmacia (GE
Healthcare, Uppsala, Sweden) and was used for plasmid propagation.M. bovis BCG
Pasteur 1173P2 was obtained from the strain collection of the Institute Pasteur, Paris,
France (strain #CIP105050).M. bovis BCG Denmark (1331) was obtained in the form
of a vaccine production lot through the Statens Serum Institute, Copenhagen,
Denmark. M. bovis BCG Frappier (Montreal, ATCC #35735) primary lot, dated 1973,
lot number 1376141, was obtained from the American Type Culture Collection
(ATCC), Rockville, MD, USA. The Frappier strain held by ATCC was initially
transferred from the Institut Pasteur to Frappier’s Institute in Montreal in 1937, was
integrated in the Trudeau Mycobacterial Culture Collection and finally went to the
ATCC. A vaccine production lot 547-1104 K. 1491 of M. bovis BCG Russia
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6(corresponding to ATCC #35740) was obtained through Medgamal Inc. (TD
Allergen, Moscow, Russia). This was the first documented daughter strain distributed
by Institut Pasteur in 1924
21
going directly to Russia. It is referred as an ‘early strain’
with regards to its genetic characteristics (regions of difference, insertional elements,
antigen expression pattern).
The identity of the BCG substrains was confirmed using morphological features
(roughling, generation time), PCR amplification and sequencing of described regions
of difference as described by
22
.
Media, transformation and DNA damage induction. The media for growing E. coli
DH5, and substrains of Mycobacterium bovis BCG have been described
previously
23
. M. bovis BCG substrains were revitalised by addition of 1 mL
Middlebrook 7H9 medium to a lyophilized batch. For DNA damage induction
experiments M. bovis BCG was grown in Middlebrook 7H9 medium with addition of
10% (vol/vol) OADC in motionless tissue culture flasks in a 37 °C incubator.
Published protocols were followed for the preparation of electrocompetent cells of
mycobacteria and for electroporation
23
. The recA mutants of BCG Pasteur, Denmark
and Frappier were generated by allelic replacement using a suicide knock-out vector
(Supplementary Methods online).
To induce DNA damage, mitomycin C (0.2 g ml
-1
) was added to 20 mL of
growing cultures (at an OD600 of 0.6) and incubated for 24 h. Thereafter, bacteria
were harvested by centrifugation and prepared for cell lysis.
DNA isolation, sequencing and alignment. DNA was extracted from solid cultures
grown on 7H10. The recA gene was amplified from genomic DNA (10 ng) by Pfu
DNA polymerase using primers #1 and #2. The product was cleaned via gel
purification and sequenced using primers #1 to #9 (Suppl. Table 2 online) using an
ABI PRISM 310 DNA sequencer (Applied Biosystems, Forster City, CA, USA). The
sequences were aligned using Lasergene (DNASTAR, Madison, WI, USA) SeqMan
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7(version 6). The aligned sequence was compared via BLAST software to the recA
sequence of M. bovis BCG substrain Pasteur 1173P2
1
.
Preparation of cell-free extracts. Untreated and mitomycin-C-treated bacteria were
harvested by centrifugation, washed with PBS buffer (pH 7.2) and resuspended in 300
L PBS containing 0.5% protease inhibitor cocktail (Sigma). Bacteria were lysed in
screw-cap tubes in a water immersion (ice-chilled) sonicator (Elma, Singen,
Germany), using maximum duty-cycle during 1 h 20 min with a cooling interval
every 20 min. The crude lysate was clarified by spinning at 1 000 x g during 10 min.
Western blotting. Cell-free extracts corresponding to 50 g total protein
(quantification via Bradford assay) were used for Western blot analyses. Following
SDS-PAGE in a 13.3% polyacrylamide gel, proteins were blotted to a PVDF
membrane using a semi-dry blotter (Biorad, Hercules, CA, USA) at constant current
(0.3 A) for 30 min. Equal loading of proteins was confirmed by Coomassie staining,
and by blotting with antibodies against the constitutively expressed mycobacterial
protein (KatG).
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Figure 1 Comparative alignment of DNA sequencing electropherograms for
M. bovis BCG Pasteur 1173P2 and BCG Russia displaying the insertional
SNP (C414) in the recA gene of BCG Russia. As a consequence Leu139 is
changed to Ala, which is immediately followed by a premature stop codon
(D140*). Nucleotide and amino acid numbering starts at the recA initiation
codon.
Figure 2 Western blot analysis of cell-free protein extracts from different BCG
preparations (with and without SOS response induction by mitomycin C; 50
g protein per lane). Detection was carried out using a polyclonal mouse -
RecA antibody (1:1000), mature RecA protein has an approximate molecular
weight of 38 kDa. A polyclonal mouse -KatG antibody was used as loading
control (1:2500); KatG protein has a molecular weight of 81 kDa. Bands
migrating around 50 kDa are unspecific; secondary antibody was HRP-
conjugated goat-anti-mouse antibody (1:2500).
Figure 3 Genealogy of BCG vaccine substrains, modified from1 with
permission, copyright (2007) National Academy of Sciences, U.S.A.,
displaying the original virulent ancestor strain Mycobacterium bovis (isolated
by Nocard in 1908) and the subsequent series of genomic alteration including
deletions of regions of difference (RD), single nucleotide polymorphisms, and
duplications of genomic regions. The recA alteration (recA_D140*) is added to
the scheme.
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